CR20200415A - Formas y mètodos de dosis para bupropión enantioméricamente enriquecido o puro - Google Patents

Formas y mètodos de dosis para bupropión enantioméricamente enriquecido o puro

Info

Publication number
CR20200415A
CR20200415A CR20200415A CR20200415A CR20200415A CR 20200415 A CR20200415 A CR 20200415A CR 20200415 A CR20200415 A CR 20200415A CR 20200415 A CR20200415 A CR 20200415A CR 20200415 A CR20200415 A CR 20200415A
Authority
CR
Costa Rica
Prior art keywords
bupropion
dosage forms
enantiomerically enriched
methods
pure bupropion
Prior art date
Application number
CR20200415A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of CR20200415A publication Critical patent/CR20200415A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Abstract

<p>En la presente descripción se describen formas de dosificación de (<em>S</em>)-bupropión enriquecido enantioméricamente o (<em>R</em>)-bupropión enriquecido enantioméricamente. El (<em>S</em>)-bupropión o (<em>R</em>)- bupropión puede estar enriquecido con deuterio o pueden tener una abundancia isotópica natural. Estas formas de dosificación pueden administrarse, con la alimentación o en 5 ayunas, para tratar una afección mencionada en la presente descripción, para lograr un cierto parámetro farmacocinético de un bupropión o un metabolito de un bupropión, y/o para mejorar los niveles plasmáticos de dextrometorfano.</p>
CR20200415A 2018-02-23 2019-02-25 Formas y mètodos de dosis para bupropión enantioméricamente enriquecido o puro CR20200415A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US201962809480P 2019-02-22 2019-02-22
PCT/US2019/019445 WO2019165379A1 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Publications (1)

Publication Number Publication Date
CR20200415A true CR20200415A (es) 2021-02-03

Family

ID=67688503

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200415A CR20200415A (es) 2018-02-23 2019-02-25 Formas y mètodos de dosis para bupropión enantioméricamente enriquecido o puro

Country Status (18)

Country Link
EP (1) EP3755312A4 (es)
JP (2) JP2021513998A (es)
KR (2) KR20230075531A (es)
CN (1) CN112087999A (es)
AU (2) AU2019223187B2 (es)
BR (1) BR112020017179A2 (es)
CA (1) CA3092076A1 (es)
CL (1) CL2020002166A1 (es)
CR (1) CR20200415A (es)
EC (1) ECSP20060179A (es)
IL (1) IL276871A (es)
MA (1) MA51914A (es)
MX (1) MX2020008704A (es)
NI (1) NI202000056A (es)
NZ (1) NZ767378A (es)
PE (1) PE20211752A1 (es)
SG (1) SG11202008056SA (es)
WO (1) WO2019165379A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
CN114423417A (zh) * 2019-09-20 2022-04-29 艾克萨姆治疗公司 用于对映体富集的或纯的安非他酮的剂型和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2483499A (en) * 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (+)-bupropion
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
ATE454138T1 (de) * 2003-08-08 2010-01-15 Biovail Lab Int Srl Tablette mit modifizierter freisetzung von bupropion hydrochlorid
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US9198905B2 (en) * 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion

Also Published As

Publication number Publication date
NI202000056A (es) 2021-01-11
MA51914A (fr) 2020-12-30
WO2019165379A1 (en) 2019-08-29
PE20211752A1 (es) 2021-09-06
NZ767378A (en) 2024-03-22
AU2019223187A1 (en) 2020-09-17
BR112020017179A2 (pt) 2020-12-22
AU2022204521A1 (en) 2022-07-21
KR20230075531A (ko) 2023-05-31
ECSP20060179A (es) 2020-12-31
EP3755312A1 (en) 2020-12-30
JP2021513998A (ja) 2021-06-03
CA3092076A1 (en) 2019-08-29
IL276871A (en) 2020-10-29
EP3755312A4 (en) 2022-03-16
CL2020002166A1 (es) 2020-10-23
CN112087999A (zh) 2020-12-15
JP2022153638A (ja) 2022-10-12
SG11202008056SA (en) 2020-09-29
MX2020008704A (es) 2020-12-07
AU2019223187B2 (en) 2022-07-28
KR20210003091A (ko) 2021-01-11

Similar Documents

Publication Publication Date Title
CR20200415A (es) Formas y mètodos de dosis para bupropión enantioméricamente enriquecido o puro
JO3522B1 (ar) تركيب صيدلاني يتألف من كريات حمراء تغلف إنزيم يعتمد على بيريدكسال الفوسفات والعامل المساعد له
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
WO2020061486A3 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
NZ610526A (en) Deuterium enriched rasagiline
MX2019014113A (es) Terapia combinada para trastornos neuropsiquiatricos sensibles al antagonista de nmdar.
MX363719B (es) Codificación de audio alineada por fragmentos.
AU2017247046A1 (en) Synchronizing ancillary data to content including audio
MX2023004028A (es) Dispositivo y metodo para la dispersion de no de concentracion alta con gas de terapia de inhalacion.
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
GEP20227384B (en) Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment
MX2021001845A (es) Un medicamento combinado que comprende fenilefrina y paracetamol.
CR20220119A (es) Formas de dosificación para bupropión enantioméricamente enriquecido o puro
CR20200616A (es) Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión
Vourvahis Lersivirine/methadone
MX2022008055A (es) Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas.
Tomita Thrombocytopenia, neutropenia and proteinuria: case report
UA99842U (ru) Способ проводниковой анестезии
Atay Nocturnal enuresis: case report
Lin Hypertension, diarrhoea and hand-foot syndrome: 4 case reports
MX2018010367A (es) Titulacion de cebranopadol.
UA89024U (uk) Спосіб комплексного лікування уретеролітіазу
UA89127U (uk) Спосіб лікування антифосфоліпідного синдрому
UA105586U (uk) Спосіб лікування печінкової енцефалопатії